Cargando…

The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma

Myeloma is characterized by extensive inter-patient genomic heterogeneity due to multiple different initiating events. A recent multi-region sequencing study demonstrated spatial differences, with progression events, such as TP53 mutations, frequently being restricted to focal lesions. In this revie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasche, Leo, Kortüm, K. Martin, Raab, Marc S., Weinhold, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429294/ https://www.ncbi.nlm.nih.gov/pubmed/30871078 http://dx.doi.org/10.3390/ijms20051248

Ejemplares similares

Novel immunotherapies in multiple myeloma – chances and challenges
por: Rasche, Leo, et al.
Publicado: (2021)

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice
por: Zhou, Xiang, et al.
Publicado: (2022)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials
por: Fleischer, Anna, et al.
Publicado: (2023)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
por: Zhou, Xiang, et al.
Publicado: (2020)

COVID-19 infection in patients with multiple myeloma: a German-Chinese experience from Würzburg and Wuhan
por: Zhou, Xiang, et al.
Publicado: (2020)

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
por: Rasche, L., et al.
Publicado: (2017)

Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
por: Loda, Sophia, et al.
Publicado: (2019)

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
por: Cerchione, Claudio, et al.
Publicado: (2022)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
por: Giesen, Nicola, et al.
Publicado: (2022)

The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level
por: Schinke, Carolina, et al.
Publicado: (2023)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
por: Kropivsek, Klara, et al.
Publicado: (2023)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma
por: Davies, Faith E., et al.
Publicado: (2018)

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma
por: Steinbach, Mary, et al.
Publicado: (2022)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells
por: Kehl, Niklas, et al.
Publicado: (2022)

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma
por: Issa, Mark E., et al.
Publicado: (2017)

Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
por: Schinke, Carolina, et al.
Publicado: (2023)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
por: Stein, Caleb K., et al.
Publicado: (2017)

(Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI
por: Bauer, Fabian, et al.
Publicado: (2023)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations
por: Zhao, Duoduo, et al.
Publicado: (2023)

High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
por: Solimando, Antonio Giovanni, et al.
Publicado: (2019)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
por: Tirier, Stephan M., et al.
Publicado: (2021)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

Pathway-Directed Therapy in Multiple Myeloma
por: John, Lukas, et al.
Publicado: (2021)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
por: Bobin, Arthur, et al.
Publicado: (2020)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Transient regulatory T-cell targeting triggers immune control of multiple myeloma and prevents disease progression
por: Dahlhoff, Julia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rtro63gh020ovgbd5m4khvs319